Owners, management and financials
CVR: 32323596
EUR 229,581,000
Gross profit
Net result: EUR 134,982,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Jan Møller Mikkelsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 29 June 2012
CVR · view overview
0 employees
Annual report 2025 · average
Director registered: Jan Møller Mikkelsen
CVR · 29/06/2012
View the full event history
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.
Source: annual report 2025, Danish Business Authority
The financial health of ASCENDIS PHARMA BONE DISEASES A/S appears precarious, marked by significant losses and negative equity over the past several years. In 2025, the company reported a gross profit of €229.58 million, a notable recovery from previous years, but still faced a concerning equity deficit of €372.18 million. The trend shows a decline in profitability from 2021 to 2024, with losses peaking at €139.09 million in 2024. While the recent gross profit indicates potential for improvement, the ongoing negative equity and previous years' losses raise concerns about the company's long-term viability and financial stability within the pharmaceutical manufacturing industry.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 229.6 mio. EUR | 135 mio. EUR | 58.7 mio. EUR | -372.2 mio. EUR | 0 | |
| 202401/01/2024 – 31/12/2024 | -34 t. EUR | -139 t. EUR | 15 t. EUR | -507 t. EUR | 0 | |
| 202301/01/2023 – 31/12/2023 | -112.3 mio. EUR | -119 mio. EUR | 39.6 mio. EUR | -368.1 mio. EUR | 0 | |
| 202201/01/2022 – 31/12/2022 | -66.6 mio. EUR | -72.2 mio. EUR | 18.5 mio. EUR | -249.2 mio. EUR | 0 | |
| 202101/01/2021 – 31/12/2021 | -58 mio. EUR | -61.8 mio. EUR | 18.3 mio. EUR | -177 mio. EUR | 0 | |
| 202001/01/2020 – 31/12/2020 | -38.8 mio. EUR | -41.3 mio. EUR | 18.1 mio. EUR | -115.1 mio. EUR | 0 | |
| 201901/01/2019 – 31/12/2019 | -27.5 mio. EUR | -28.8 mio. EUR | 14.9 mio. EUR | -73.8 mio. EUR | 0 | |
| 201801/01/2018 – 31/12/2018 | -18.9 mio. EUR | -19.8 mio. EUR | 13.5 mio. EUR | -45 mio. EUR | 0 | |
| 201701/01/2017 – 31/12/2017 | -16.2 mio. EUR | -16.6 mio. EUR | 3.2 mio. EUR | -25.2 mio. EUR | 0 | |
| 201601/01/2016 – 31/12/2016 | -6.4 mio. EUR | -6.6 mio. EUR | 1.3 mio. EUR | -8.6 mio. EUR | - | |
| 201501/01/2015 – 31/12/2015 | -137 t. EUR | -279 t. EUR | 241 t. EUR | -1.9 mio. EUR | - | |
| 201401/01/2014 – 31/12/2014 | -1.2 mio. EUR | -1.3 mio. EUR | 615 t. EUR | -1.7 mio. EUR | - | |
| 201301/01/2013 – 31/12/2013 | -4.1 mio. | -4.1 mio. | 2.3 mio. | -4 mio. | - |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of ASCENDIS PHARMA BONE DISEASES A/S is 32323596.
ASCENDIS PHARMA BONE DISEASES A/S is owned by ASCENDIS PHARMA A/S.
The management of ASCENDIS PHARMA BONE DISEASES A/S consists of Jan Møller Mikkelsen.
The board of ASCENDIS PHARMA BONE DISEASES A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, ASCENDIS PHARMA BONE DISEASES A/S reported a gross profit of EUR 229,581,000.
ASCENDIS PHARMA BONE DISEASES A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2025. Gross profit came to DKK 229,581,000, and the net result was DKK 134,982,000.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2024. Gross profit came to DKK -34,018, and the net result was DKK -139,088.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2023. Gross profit came to DKK -112,332,138, and the net result was DKK -118,956,906.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2022. Gross profit came to DKK -66,598,343, and the net result was DKK -72,197,542.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2021. Gross profit came to DKK -57,981,885, and the net result was DKK -61,825,261.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2020. Gross profit came to DKK -38,797,098, and the net result was DKK -41,299,834.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2019. Gross profit came to DKK -27,475,665, and the net result was DKK -28,817,684.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2018. Gross profit came to DKK -18,881,606, and the net result was DKK -19,845,085.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2017. Gross profit came to DKK -16,157,965, and the net result was DKK -16,623,961.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2016. Gross profit came to DKK -6,444,960, and the net result was DKK -6,620,900.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2015. Gross profit came to DKK -137,219, and the net result was DKK -278,875.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2014. Gross profit came to DKK -1,220,383, and the net result was DKK -1,336,808.
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2013. Gross profit came to DKK -4,105,157, and the net result was DKK -4,115,409.
ASCENDIS PHARMA BONE DISEASES A/S has published its interim report for the period June 29, 2012 – December 31, 2012.
As of June 29, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ASCENDIS PHARMA BONE DISEASES A/S.
As of June 29, 2012, Michael Wolff Jensen has joined the board of directors of ASCENDIS PHARMA BONE DISEASES A/S.
As of June 29, 2012, Jan Møller Mikkelsen has joined the board of directors of ASCENDIS PHARMA BONE DISEASES A/S.
As of June 29, 2012, Anni Lotte Kirstine Pedersen has joined the board of directors of ASCENDIS PHARMA BONE DISEASES A/S.
As of June 29, 2012, Jan Møller Mikkelsen is registered as adm. dir. of ASCENDIS PHARMA BONE DISEASES A/S.
As of June 29, 2012, ASCENDIS PHARMA A/S is registered as an owner of ASCENDIS PHARMA BONE DISEASES A/S with an ownership share of 100%.
ASCENDIS PHARMA BONE DISEASES A/S was founded on June 29, 2012.
Companies in the same industry and area
CVR 29918791
CVR 32323502
CVR 32323537
CVR 37011185
CVR 46029518
